Silence Therapeutics' divesiran hits its Phase 2 target in polycythemia vera, setting up a Phase 3 trial
August 10, 2026 07:31 AM EDT
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome' - Silence Therapeutics (NASDAQ:
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics aims at Takeda with new data in rare blood cancer
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Cancer treatment makes tumor vulnerable to immune system attack, research finds | The Jerusalem Post
Skylar Bio kicks off new gene therapy trial for deafness
